US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies
Phase 1
Recruiting
- Conditions
- High Risk Myeloid MalignanciesCord Blood Transplant
- Interventions
- Biological: ECT-001-CB (UM171-Expanded Cord Blood Transplant)
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- ExCellThera inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04990323
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
US Phase I Study of ECT-001-CB in Patients With Sickle-Cell Disease
Phase 1
Withdrawn
- Conditions
- Sickle Cell DiseaseUmbilical Cord BloodHematopoietic Cell Proliferation
- Interventions
- Biological: ECT-001-CB (UM171-Expanded Cord Blood Transplant)
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2022-07-05
- Lead Sponsor
- ExCellThera inc.
- Registration Number
- NCT04594031
- Locations
- 🇺🇸
Stanford University School of Medicine, Palo Alto, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia
Phase 2
Active, not recruiting
- Conditions
- Cord Blood TransplantHigh Risk Hematological Malignancy
- Interventions
- Biological: ECT-001-CB (UM171-Expanded Cord Blood Transplant)
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- ExCellThera inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04103879
- Locations
- 🇺🇸
Fred Hutchinson / University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸University of Colorado School of Medicine. Anschutz Medical Campus, Aurora, Colorado, United States
🇳🇱Erasmus Medical Center, Rotterdam, GD, Netherlands
© Copyright 2025. All Rights Reserved by MedPath